BACKGROUND: Pancreatic neuroendocrine neoplasms with a Ki-67 labeling index greater than 20% were reclassified in 2017 by the World Health Organization into well differentiated (WD) and poorly differentiated grade 3 neuroendocrine carcinoma (NEC). The authors describe the cytologic features of grade 3 WD pancreatic neuroendocrine neoplasms compared with grade 2 neoplasms and NEC. METHODS: Fine-needle aspirates from 65 pancreatic neuroendocrine neoplasms were reviewed, and their cytomorphologic features were compared across grade 2, WD grade 3, and PD small cell type (PD-S), large cell type (PD-L), and type not otherwise specified (PD-NOS) neoplasms. RESULTS: The 65 aspirates consisted of 19 grade 2 neoplasms, 32 WD grade 3 neoplasms, and 14 NECs (6 PD-S, 5 PD-L, and 3 PD-NOS). The medians Ki-67 proliferation index was 11% (range, 3.2%-17%) in grade 2 neoplasms, 40% (range, 21%-89%) in WD grade 3 neoplasms, 80% (range, 63%-95%) in PD-S neoplasms, 39% (range, 25%-61%) in PD-L neoplasms, and 70% (range, 30%-80%) in PD-NOS neoplasms. Both grade 2 and WD grade 3 neoplasms were associated with plasmacytoid morphology and smooth nuclear contours, but WD grade 3 neoplasms had significant increases in abundant cytoplasm (72% vs 17%; P 5 .007), nuclear tangles (75% vs 42%; P 5 .006), and apoptosis (86% vs 58%; P 5 .005). Compared with NECs, WD grade 3 neoplasms had increased plasmacytoid morphology (75% vs 7%; P < .001), smooth nuclear contours (94% vs 64%; P 5 .02), round nuclei (59% vs 21%; P 5 .01), and less pleomorphism (13% vs 50%; P 5 .004), molding (9% vs 79%; P < .001), and necrosis (13% vs 43%; P 5 .003). WD grade 3 neoplasms had less pleomorphism (13% vs 50%; P 5 .04), less necrosis (13% vs 60%; P 5 .04), and more plasmacytoid morphology (75% vs 20%; P 5 .03) than PD-L. CONCLUSIONS: The prevalence of cytologic features differs in WD grade 3 pancreatic neuroendocrine neoplasms compared with grade 2 neoplasms and NECs, and these differences assist in the recognition of this newly classified entity. Cancer Cytopathol 2018;126:326-35.
INTRODUCTION
Recently, a new diagnostic category, well differentiated (WD) grade 3 pancreatic neuroendocrine tumor (PanNET), was created by the 2017 World Health Organization (WHO) for WD gastropancreatic NETs with Ki-67 proliferation or mitotic rates exceeding 20%. 1 Previously, neoplasms with proliferation rates greater than 20% were classified as poorly differentiated (PD) neuroendocrine carcinomas (NECs) of small (PD-S) or large (PD-L) cell types. However, a 2-tiered subclassification of this category is necessary, because it has become clear that the grade 3 tumors consist of WD and PD neuroendocrine neoplasms, and theses 2 classes have underlying differences not only in morphology but also in genotype, immunophenotype, behavior, and treatment response. [2] [3] [4] [5] [6] [7] WD PanNETs typically present as local or locally advanced disease. Mortality for patients with WD PanNETs who are not cured by surgery usually is related to progressive disease within the liver. 8 Rarely, WD grade 3 PanNETs present as de novo histologically with a uniform grade 3 proliferation rate or as morphologically distinct areas with grade 3-level proliferation in association with an otherwise grade 1 or 2 neoplasm. More commonly, these tumors have an increased proliferation rate over the course of disease progression. 6, 7 In contrast, NEC is universally aggressive and advanced at presentation. Patients with NEC are managed with platinum-based therapies as a first line of treatment but often have an abbreviated response with poor survival. 7 Emerging genotypes for WD PanNETs include mutations of death domain-associated protein (DAXX), a thalassemia/mental retardation syndrome X (ATRX), and menin (MEN1); whereas NECs exhibit more similarity to conventional pancreatic adenocarcinoma and may have mutations of the retinoblastoma 1 (RB1), Kirsten rat sarcoma oncogene homolog (KRAS), and tumor protein 53 (TP53) genes. 3, 4, 9 Loss of immunohistochemical labeling for DAXX, ATRX, and RB1 and abnormal expression of p53 reportedly correlate well with mutation status. 10 The diagnosis of pancreatic neuroendocrine neoplasms requires accurate determination of grade and differentiation. Grade can be determined objectively using markers of proliferation, including mitotic activity and/or Ki-67 proliferation; however, currently, differentiation is initially based on subjective morphologic assessment. Most WD PanNETs are low grade and have a typical plasmacytoid cytomorphology that is easily recognized on fineneedle aspiration (FNA) specimens. 11 NECs also have dis- In the current study, we compare the cytomorphology of WD grade 3 neoplasms with that of grade 2 neoplasms and NECs using a cohort of well characterized tumors classified by review of prior and concurrent histology; ancillary studies (Ki-67 proliferation index, immunohistochemistry [loss of RB1, DAXX, ATRX, and p53 protein expression]); mutations in DAXX, ATRX, RB1, TP53, MEN1, or KRAS detected by targeted mutation analysis; and consensus review.
MATERIALS AND METHODS

Case Selection
Patients who had FNA specimens available from pancreatic neuroendocrine neoplasms (primary or metastatic) were selected retrospectively by 1 author (C.S.S.) from the pathology database at Memorial Sloan Kettering Cancer Center with institutional review board approval during the period from August 2002 to December 2016. Clinical data were obtained from the electronic medical record, including age of diagnosis, sex, stage of presentation, and therapeutic agents received before biopsy. Therapeutic agents were divided among the following classes: hormone only (octreotide), alkylating agent (dacarbazine, temozolomide), cytotoxic chemotherapy (irinotecan, capecitabine, 5-fluorouracil, etoposide), targeted agent (everolimus, sunitinib), and platinum based (carboplatin, oxaliplatin). 8 
Cytologic Features Assessment
Slides were de-identified immediately after retrieval from the slide archive (T.D.D.). Two authors reviewed all slides from each case independently (C.S.S. and V.W.K.S) and were blinded to clinical history and ancillary information. Cases were re-reviewed together for consensus in instances of disagreement. The cytology preparations consisted of the following: air-dried Diff-Quik, ThinPrep, and alcoholfixed smears or cell blocks stained with hematoxylin and eosin. The following cytologic features were assessed: large nuclear size, nuclear pleomorphism, round nucleus, smooth nucleus contour, nucleus angulation, fine chromatin, single prominent nucleolus, presence of plasmacytoid morphology, abundant cytoplasm, nuclear tangles, nucleus molding, and necrosis. Large nuclear size was defined as greater than 5 times the size of a lymphocyte. Single prominent nucleoli were determined by visibility at low-power magnification. Abundant cytoplasm was defined as greater than 3 times the size of the nucleus. Apoptotic debris was counted in 10 high-power fields (340 objective; Olympus BX43; Olympus, Tokyo, Japan) and was recorded as present, absent, or >5. Mitoses were counted in 10 highpower fields (340 objective; Olympus BX43; Olympus) as any present, absent, or >5. Comparison of cytologic features was performed across the tiers of grade and differentiation. Categorical variables were compared using the Fisher exact test and continuous variables were compared using the Wilcoxon rank-sum test with the STATA 13 statistical software package (Stata Corporation, College Station, TX). The threshold for statistical significance was P < .05.
Immunohistochemistry
Additional immunohistochemical studies were performed on core biopsies with available material. The antibodies used included RB1 (1:50 dilution; 13A10; Dako, Carpenteria, CA), anti-ATRX (1:500 dilution; Sigma-Aldrich Corporation, St Louis, MO), anti-DAXX (1:300 dilution; Sigma-Aldrich Corporation), P53 (1:250 dilution; D07; Dako), and anti-Ki-67 (prediluted; 30-9; Ventana Medical Systems, Inc, Tucson, AZ). The BenchMark XT automated equipment (Ventana Medical System Inc) was used for DAXX, ATRX, p53, and Ki-67 immunohistochemistry; whereas the Leica BOND automated system (Leica Biosystems, Wetzlar, Germany) was used for RB1 immunohistochemistry. Abnormal staining was assessed as complete loss of DAXX, ATRX, and RB1 nuclear protein expression in the presence of positive nuclear staining in non-neoplastic cells. Abnormal p53 labeling was defined as strong nuclear positivity in >25% of nuclei or complete absence of staining in the presence of a positive internal control. The Ki-67 proliferation rate was determined previously for all included cases by manual counting on core biopsy, cell block, and/or alcohol fixed cytology smears; and the methods used are described in the our previous work. 13 For concurrently obtained cytology/biopsy, the highest Ki-67 rate was used to assign grade for that specific biopsy using 2017 WHO criteria.
Tumor Classification
For tumor classification, a complete pathology review was performed for each patient using slides from the FNA specimen, core biopsies, and resections; and the results of ancillary testing (previously performed and for the current study) were compiled on any available tumor specimens (immunohistochemistry and targeted sequencing analysis by Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets, a custom, nextgeneration sequencing array of 410 cancer-associated genes). 10, 12, 14 Testing had been performed for 28 patients on material from 21 liver core biopsies, 1 lymph node excision, 5 pancreatectomies, and 1 cell pellet from a liver FNA. Cases lacking material for ancillary testing were reviewed for consensus opinion on morphologic differentiation by 2 of 3 cytopathologists (C.S.S., D.C., and M.D.R.). All neoplasms were definitively classified as grade 2, WD-grade 3, or NEC by applying the criteria outlined in Table 1 . 
RESULTS
Clinical Characteristics
The study included 65 FNA specimens from pancreatic neuroendocrine neoplasms obtained from 62 patients, including 19 grade 2 specimens, 32 WD grade 3 specimens, and 14 NECs (6 PD-S, 5 PD-L, and 3 PD-not otherwise specified [PD-NOS]) ( Table 2 ). Comparing the clinical features between grade 2 and WD grade 3, we observed no significant differences in age of diagnosis, sex, stage of presentation, anatomic site of FNA, prior resection of primary tumor, or biopsy indication for FNA ( Table 2) . Most of the clinical parameters were similar between WD and NEC specimens, with 2 exceptions: the distribution of anatomic site for FNA differed (P 5 .04), and the FNA biopsy more commonly was taken at the time of initial diagnosis rather than at the time of disease progression (P < .001). Overall, advanced disease at presentation was heavily represented in all groups, with 69% and 93% of patients with WD neoplasms and NECs presenting with stage IV disease (the American Joint Committee on Cancer AJCC Cancer Staging Manual, seventh edition) ( Table 2) . The majority of all FNAs (80%) had a concurrently obtained core biopsy. At the time of FNA, the majority of patients with WD neoplasms and NECs either had received no prior therapy or had received only hormonebased (cytostatic) therapy (patients with WD neoplasms, 66%; patients with NEC, 87%) ( Table 2) . No significant differences were observed in the classes of therapeutic agents received before biopsy (P > .05). 
Tumor Classification
Approximately one-half of patients (52%) had multiple criteria supporting classification (Table 3) . A prior history of a grade 1 or 2 neoplasm was the most common supporting criterion for grade 2/WD grade 3 neoplasms, a requirement that was met by 63% of patients. In those with grade 2/WD grade 3 neoplasms, mutations of DAXX or ATRX were detected in 12 of the 22 (55%) tested cases. MEN1 mutations were present in 14 patients with grade 2/WD grade 3 neoplasms, of whom 11 also had DAXX or ATRX mutations. Immunohistochemistry for DAXX and ATRX was performed on 30 specimens, and loss of either DAXX or ATRX protein expression was identified on 6 (19%) (Supporting Table 1 ). There were 3 cases in which both Abbreviations: ATRX, a thalassemia/mental retardation syndrome X; DAXX, death domain-associated protein; IHC, immunohistochemistry; KRAS, Kirsten rat sarcoma oncogene homolog; MEN1, menin 1; NOS, not otherwise specified; PD, poorly differentiated; RB1, retinoblastoma 1; TP53, tumor protein 53; WD, well differentiated. a Consensus review was used in cases without ancillary supporting information. b TP53 mutations were identified in 3 cases that had additional criteria supporting WD. Original Article mutation testing and immunohistochemistry for DAXX and ATRX were performed, and loss of protein expression corresponded with mutation in 2 cases; the third, discrepant case is described in detail below. Classification as NEC was supported by mutation analysis in 21% of cases and by immunohistochemistry (loss of RB1 expression) in 43% (Supporting Tables 1  and 2 ). A few (5 cases; 13%) WD grade 3 specimens were classified by fulfilling only the criterion of consensus on morphology (16%), but nearly one-half of NECs required classification by consensus review (43%) ( Table 3 ). Immunohistochemistry for p53 was performed on 21 cases, and none had abnormal expression.
In the data we collected for classification, there were 2 instances of conflicting results in the 16 cases for which both IHC and molecular testing had been performed. In 1 instance, a WD grade 3 neoplasm had both DAXX and ATRX mutations, and DAXX nuclear staining was absent, whereas ATRX was retained. A second instance was a TP53-mutated, WD, grade 3 specimen without abnormal p53 protein expression. Neither discrepancy had an effect on tumor classification, because other criteria supported what we believed was the correct classification. All other results for mutation testing and immunohistochemical staining for protein expression indicated a correlation, including the 2 cases with RB1 mutations that had loss of RB1 protein expression.
Three cases met criteria for both PD and WD, because they had coexisting mutations of TP53 and/or KRAS and either DAXX, MEN1, and/or ATRX. One sample from a patient who underwent prior grade 2 resection and had a Ki-67 proliferation rate <20% was classified as WD. The other 2 patients had grade 3 tumors with consensus WD morphology and had received prior therapy with alkylating or platinum-based agents.
Morphologic Comparison
Morphologic features and Ki-67 proliferation rates were compared across the tiers of differentiation and grade, and those results are summarized in Tables 4, 5 , and 6. Features classically described in WD-PanNET, including plasmacytoid morphology and smooth nuclear contours, were associated significantly with grade 2/WD grade 3 cases compared with NEC (Fig. 1, Table 4 ). Grade 2 and WD grade 3 cases had low rates of molding (5% and 9%, respectively) and pleomorphism (5% and 13%, respectively) (Table 4) . Necrosis was not observed in grade 2 samples but was present occasionally in WD grade 3 samples (13%), as expected. Most of the features that occurred at a significantly higher proportion in WD grade 3 versus grade 2 neoplasms reflected proliferative activity, including apoptosis (any [P 5 .005] and >5 per high-power field [P 5 .001]) and nuclear tangles (P 5 .006) ( Table 4 , Fig.  2 ). In addition, more WD grade 3 cases had abundant cytoplasm compared with grade 2 cases (P 5 .007) ( Fig. 2 ; Table 4 ). Evidence of proliferation was associated with NEC, as expected, including conspicuous mitoses (>5 of 10 high-power fields; P 5 .03). Other features significantly associated with PD compared with grade 2 and 3 cases included pleomorphic nuclei (P 5 .004), angulated nuclei (P < .001), molding (P < .001), lack of plasmacytoid morphology (P < .001), and less round nuclei (P 5 .01) (Fig. 1) . Comparing WD grade 3 with PD-L, we observed that WD grade 3 samples had less pleomorphic nuclei (P 5 .04), more plasmacytoid cells (P 5 .03), and fewer cases with necrosis (P 5 .04) ( Fig. 2 ; Table 5 ). Also as expected, frequent molding and lack of abundant cytoplasm were observed in PD-S (Fig. 1, Table 6 ). There were too few samples of NEC to compare morphologic features within the NEC category.
Plasmacytoid morphology was absent in 11 (22%) grade 2 and WD grade 3 cases, and 9 of those were grade 3. The most common features observed in WD NETs without plasmacytoid morphology were angulated nuclei, nuclear tangles, and apoptosis (Fig. 2) .
The median Ki-67 proliferation rates for each tier were as follows: grade 2, 11% (range, 3.2%-17%); WD grade 3, 40% (range, 21%-89%); PD-S, 80% (range, 63%-95); PD-L, 39% (range, 25%-61%); and PD-NOS, 70% (range, 30%-80%). Notably, there were significant differences among the NEC subtypes and WD grade 3 neoplasms had median and range values similar to those in PD-L.
DISCUSSION
Separating WD-NET from NEC has major prognostic implications and directly impacts therapeutic decision making. 8 Molecular analysis and immunohistochemistry for loss of mutant protein expression (eg, DAXX, ATRX, MEN1, RB1) can be very useful in supporting differentiation when a characteristic abnormality is identified, but these tests are not universally available, may not be feasible, and may not identify a genotype with known significance. 10 To enhance the cytologic diagnosis of these neoplasms, we compared grade 2 and WD grade 3 neuroendocrine cytomorphology. We gathered as much ancillary information as feasible using available tumor material and records of prior testing to provide the best classification of the included neoplasms. Classic descriptions of WD NET cytology point out plasmacytoid forms with round nuclei resembling benign islet cells. 15 The majority of grade 2 and WD grade 3 neoplasms were in keeping with this description, but the increased proliferation of WD grade 3 is accompanied by morphologic changes, which might be expected with increased proliferation, because they also are observed in NEC (apoptosis, mitoses, and nuclear tangles). In addition to the presence of plasmacytoid forms, abundant cytoplasm was much more common in WD grade 3 cases than in grade 2 cases (Fig. 2) . Among the features identified at a higher rate in WD grade 3 versus grade 2 cases, abundant cytoplasm was the only feature associated with WD grade 3 and not NEC (Table 4) , although it should be noted that this feature was uniformly present in the 5 PD-L cases. Comparing WD grade 3 and PD-L cases, we observed similar Ki-67 proliferation rates, but WD grade 3 was associated with a higher rate of plasmacytoid morphology and less pleomorphic nuclei and necrosis; however, we emphasize that necrosis was present in both but usually was focal in WD grade 3 cases. Nonplasmacytoid WD cases tended to have other atypical features, including nuclear angulation, nuclear tangles, and apoptosis, which could present a problem with morphologic classification, particularly if they are grade 3. Most NECs were biopsied at initial disease presentation (86%) from a liver metastasis (78%). The differences between grade 2/WD grade 3 and NEC included nuclear atypia (eg, nuclear pleomorphism and molding) and features expected to be observed in tumors with high proliferation (eg, necrosis, apoptosis, mitoses, and nuclear tangles). In contrast, plasmacytoid morphology and round nuclei were rare to infrequent in NEC.
Many of the WD grade 3 FNAs were biopsies of disease progression; and, because of concern that morphologic features might be influenced by therapy, we recorded therapy classes used before biopsy and observed that similar classes of agents were used in grade 2 and WD grade 3 specimens.
In the current study, our objective was to describe the morphology of neoplasms that were well characterized for grade and differentiation. A Ki-67 proliferation rate was available for all tumors, and it was used to determine tumor grade because it is predictive in cytology and biopsy specimens. 13 There is no gold standard for determining differentiation, so we collected as much information as feasible to support tumor biology. A prior history of a grade 1 or 2 neoplasm was obtained in the majority of patients who had WD grade 3 specimens. When there was no prior history of a grade 1 or 2 neoplasm and the proliferation rate was >20%, targeted genotyping plus immunohistochemistry provided support for WD grade 3 in several cases. Loss of DAXX or ATRX protein expression was included as support for WD, because it has been identified as a reliable surrogate test for mutation status; however, we observed 1 instance in which ATRX protein expression was retained despite the presence of a mutation.
We acknowledge that most neuroendocrine neoplasms encountered in routine practice will likely be straightforward to diagnose. WD grade 3 cytology often maintains at least focal plasmacytoid morphology but can also have variable mitotic activity, conspicuous apoptosis, abundant cytoplasm, prominent nucleoli, molding, necrosis, and large nuclei, which may raise concern for NEC. However, in the context of a prior history of PanNET, a diagnosis of NEC should not be made.
In summary, using a well characterized cohort of pancreatic neuroendocrine neoplasms, we have identified several morphologic features associated with WD grade 3 neoplasms that may assist in the morphologic distinction of differentiation for this newly classified entity. De novo grade 3 neoplasms that are nonplasmacytoid, have pleomorphic nuclei, or have abundant cytoplasm will likely present the greatest challenge for classification; and ancillary studies, such as mutational analysis and/or immunohistochemistry for mutated proteins, are recommended.
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